

4th July 2018 | CannPal Animal Therapeutics Limited ACN: 612 791 518 | ASX:CP1

CannPal Enters into Research Agreement with Eurofins Animal Health Pty Ltd

Key Highlights

- CannPal has entered into a research services agreement with veterinary research organisation, Eurofins Animal Health Pty Ltd (Eurofins)
- Eurofins is a world leader in food, environment and pharmaceutical products testing and in agrosience and veterinary research services.
- The agreement outlines the terms in which Eurofins will be managing and conducting preclinical and clinical studies to GCP standards for the Company.
- CannPal plans to commence a pilot study of cannabinoid safety and pharmacokinetics in cats in 2H 2018 with the protocol now in development.

4th July 2018: Animal health company **CannPal Animal Therapeutics Limited (ASX:CP1)** ("CannPal" or "the Company") is pleased to announce it has entered into a research services agreement with Eurofins Animal Health Pty Ltd to develop a cannabis-derived pain treatment for cats.

The research services agreement outlines the terms in which Eurofins will design and facilitate pilot studies in cats at their research facility in NSW, Australia. Eurofins will prepare and submit ethics applications for study clearance and will be responsible for fulfilling associated ethics reporting requirements and carrying out the animal's phase of the research.

Eurofins is a world leader in food, environment and pharmaceutical products testing and in agrosience and veterinary research services that provide support to the global animal health industry. They conduct preclinical and clinical studies to GCP and GLP standards, compliant with regulatory requirements, and serve as an ideal partner to commence the Company's research on pain treatment for cats.

CannPal recently completed Phase 1A of the Pharmacokinetic and Safety study for CPAT-01, the company's lead drug candidate being developed as a pain control for dogs. The promising safety profile has given management the confidence to expand the CPAT-01 development program to include cats (CPAT-01C) as a pain control for felines.

Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most commonly used treatment for pain in cats, yet only two NSAID's have been approved for use by the FDA in the United States, and none have been approved for long-term use due to potential side effects and toxicities. The Company hopes that CPAT-01C can offer an alternative solution to help treat pain in cats in a safe and ethical way.

CannPal's Founder and Managing Director Layton Mills:

"We're delighted to announce a research collaboration with Eurofins to expand the development program of CPAT-01 into cats. We believe that there's a significant unmet



need for a feline pain treatment with a more desirable safety profile, and I strongly feel that this opportunity can create added value for our shareholders”

About CannPal Animal Therapeutics

CannPal Animal Therapeutics Limited (ASX: CP1) is a pharmaceutical-focused animal health Company researching the benefits of medical cannabis for companion animals. CannPal is researching and developing medicines derived from cannabinoids to provide veterinarians with clinically validated and standardised therapeutics to treat animals in a safe and ethical way.

CannPal has identified a significant opportunity to benefit from the rapidly growing medical cannabis and health markets by developing innovative therapeutics derived from the cannabis plant. The Company is working closely with regulatory authorities and veterinary research organisations conducting clinical trials to commercialise therapeutic products that will meet regulatory approval and support the health and well-being of companion animals. To learn more please visit: www.cannpal.com

About Eurofins

Eurofins is a world leader in food, environment and pharmaceutical products testing and provide veterinary research services which support the global animal health industry. They conduct preclinical and clinical studies to GCP and GLP standards, compliant with regulatory authority requirements for drug approval. Their technical activities involve the conduct of clinical field, pen and laboratory studies to determine the safety and efficacy of new products designed to improve animal health and welfare. Eurofins also have world class analytical capabilities.

The company has experience and expertise in veterinary chemicals, pharmaceuticals, therapeutic and prophylactic veterinary medicines, in planning and conducting of R&D programs, primary screening, individual field, pen and laboratory experiments, and out-of-season field and laboratory testing for northern hemisphere clients.

They specialise in the design, management and execution of preclinical and clinical studies in Production and Companion animals

To learn more please visit: www.eurofins.com.au

ENDS

For further information, please contact:

CannPal
Layton Mills
Founder and Managing Director
M: +61 431 302 667
E: layton@cannpal.com

Media enquiries
Julia Maguire
The Capital Network
M: +61 419 815 386
E: julia@thecapitalnetwork.com.au

 [@CannPalAT](https://twitter.com/CannPalAT)

 facebook.com/CannPal

